logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11253531 B1

PDFFull Text
Date of Patent:
Feb. 22, 2022

Filed:

May. 08, 2020

Lipid supplements for reducing nerve action potentials

Applicant:

Nutritional Therapeutics, Inc., Islandia, NY (US);

Inventors:

Garth L. Nicolson, Huntington Beach, CA (US);

Robert A. Settineri, Irvine, CA (US);

Gonzalo Ferreira de Mattos, Montevideo, UY;

Paul C. Breeding, San Antonio, TX (US);

Assignee:

NUTRITIONAL THERAPEUTICS, INC., Islandia, NY (US);

Attorney:

M. J. Ram and Associates

Primary Examiner:

Mark V Stevens

Int. Cl.
CPC ...
A61K 31/702 (2006.01); A61K 9/00 (2006.01); A23D 9/013 (2006.01); A61K 38/28 (2006.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 31/05 (2006.01); A61K 31/122 (2006.01); A61K 31/16 (2006.01); A61K 31/375 (2006.01); A61K 31/385 (2006.01); A61K 31/522 (2006.01); A61K 31/593 (2006.01); A61K 31/66 (2006.01); A61K 31/683 (2006.01); A61K 31/685 (2006.01); A61K 31/7028 (2006.01); A61K 31/716 (2006.01); A61K 31/733 (2006.01); A61K 33/22 (2006.01); A23L 29/10 (2016.01); A23L 29/244 (2016.01); A23L 33/105 (2016.01); A23L 33/115 (2016.01); A23L 33/12 (2016.01); A61P 39/06 (2006.01); A61P 21/00 (2006.01); A61K 31/661 (2006.01);
U.S. Cl.
CPC ...
A61K 31/702 (2013.01); A23D 9/013 (2013.01); A23L 29/10 (2016.08); A23L 29/244 (2016.08); A23L 33/105 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A61K 9/006 (2013.01); A61K 9/0056 (2013.01); A61K 31/05 (2013.01); A61K 31/122 (2013.01); A61K 31/16 (2013.01); A61K 31/375 (2013.01); A61K 31/385 (2013.01); A61K 31/522 (2013.01); A61K 31/593 (2013.01); A61K 31/66 (2013.01); A61K 31/661 (2013.01); A61K 31/683 (2013.01); A61K 31/685 (2013.01); A61K 31/7028 (2013.01); A61K 31/716 (2013.01); A61K 31/733 (2013.01); A61K 33/22 (2013.01); A61K 38/28 (2013.01); A61K 38/44 (2013.01); A61K 38/446 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61P 21/00 (2018.01); A61P 39/06 (2018.01); C12Y 111/01006 (2013.01); C12Y 115/01001 (2013.01); A23V 2002/00 (2013.01);
Abstract

A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating pain from overactive neurons. The phospholipid/inulin compositions were also shown to be effective in reducing depression and intestinal malfunctions including, but not limited to, diarrhea and constipation, and improving sleep pattern. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.

Find Patent Forward Citations

Loading…